Qiujun Yu1, Yi-Yin Tai1, Ying Tang1, Jingsi Zhao1, Vinny Negi1, Miranda K Culley1, Jyotsna Pilli1, Wei Sun1, Karin Brugger2, Johannes Mayr2, Rajeev Saggar3, Rajan Saggar4, W Dean Wallace4, David J Ross4, Aaron B Waxman5, Stacy G Wendell6,7, Steven J Mullett7, John Sembrat1, Mauricio Rojas1, Omar F Khan8, James E Dahlman9, Masataka Sugahara1, Nobuyuki Kagiyama1, Taijyu Satoh1, Manling Zhang1, Ning Feng1, John Gorcsan10, Sara O Vargas11, Kathleen J Haley5, Rahul Kumar12, Brian B Graham12, Robert Langer8,13, Daniel G Anderson8,13, Bing Wang14, Sruti Shiva1, Thomas Bertero15, Stephen Y Chan1. 1. Center for Pulmonary Vascular Biology and Medicine, Center for Metabolism and Mitochondrial Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, Division of Cardiology and Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA (Q.Y., Y.-Y.T., Y.T., J.Z., V.N., M.K.C., J.P., W.S., J.S., M.R., M.S., N.K., T.S., M.Z., N.F., S.S., S.Y.C.). 2. Department of Pediatrics, Paracelsus Medical University Salzburg, Austria (K.B., J.M.). 3. Department of Medicine, University of Arizona, Phoenix (Rajeev Saggar). 4. Departments of Medicine and Pathology, David Geffen School of Medicine, University of California, Los Angeles (Rajan Saggar, W.D.W., D.J.R.). 5. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.B.W., K.J.H.). 6. Department of Pharmacology and Chemical Biology (S.G.W.), University of Pittsburgh, PA. 7. Health Sciences Metabolomics and Lipidomics Core (S.G.W., S.J.M.), University of Pittsburgh, PA. 8. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge (O.F.K., R.L., D.G.A.). 9. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta (J.E.D.). 10. Division of Cardiology, Department of Medicine, Washington University in St. Louis, MO (J.G.). 11. Department of Pathology, Boston Children's Hospital, MA (S.O.V.). 12. Program in Translational Lung Research, University of Colorado Denver, Aurora, CO (R.K., B.B.G.). 13. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge (R.L., D.G.A.). 14. Molecular Therapy Lab, Stem Cell Research Center, University of Pittsburgh School of Medicine, PA (B.W.). 15. Université Côte d'Azur, CNRS UMR7275, IPMC, Sophia-Antipolis, France (T.B.).
Abstract
BACKGROUND: Deficiencies of iron-sulfur (Fe-S) clusters, metal complexes that control redox state and mitochondrial metabolism, have been linked to pulmonary hypertension (PH), a deadly vascular disease with poorly defined molecular origins. BOLA3 (BolA Family Member 3) regulates Fe-S biogenesis, and mutations in BOLA3 result in multiple mitochondrial dysfunction syndrome, a fatal disorder associated with PH. The mechanistic role of BOLA3 in PH remains undefined. METHODS: In vitro assessment of BOLA3 regulation and gain- and loss-of-function assays were performed in human pulmonary artery endothelial cells using siRNA and lentiviral vectors expressing the mitochondrial isoform of BOLA3. Polymeric nanoparticle 7C1 was used for lung endothelium-specific delivery of BOLA3 siRNA oligonucleotides in mice. Overexpression of pulmonary vascular BOLA3 was performed by orotracheal transgene delivery of adeno-associated virus in mouse models of PH. RESULTS: In cultured hypoxic pulmonary artery endothelial cells, lung from human patients with Group 1 and 3 PH, and multiple rodent models of PH, endothelial BOLA3 expression was downregulated, which involved hypoxia inducible factor-2α-dependent transcriptional repression via histone deacetylase 1-mediated histone deacetylation. In vitro gain- and loss-of-function studies demonstrated that BOLA3 regulated Fe-S integrity, thus modulating lipoate-containing 2-oxoacid dehydrogenases with consequent control over glycolysis and mitochondrial respiration. In contexts of siRNA knockdown and naturally occurring human genetic mutation, cellular BOLA3 deficiency downregulated the glycine cleavage system protein H, thus bolstering intracellular glycine content. In the setting of these alterations of oxidative metabolism and glycine levels, BOLA3 deficiency increased endothelial proliferation, survival, and vasoconstriction while decreasing angiogenic potential. In vivo, pharmacological knockdown of endothelial BOLA3 and targeted overexpression of BOLA3 in mice demonstrated that BOLA3 deficiency promotes histological and hemodynamic manifestations of PH. Notably, the therapeutic effects of BOLA3 expression were reversed by exogenous glycine supplementation. CONCLUSIONS: BOLA3 acts as a crucial lynchpin connecting Fe-S-dependent oxidative respiration and glycine homeostasis with endothelial metabolic reprogramming critical to PH pathogenesis. These results provide a molecular explanation for the clinical associations linking PH with hyperglycinemic syndromes and mitochondrial disorders. These findings also identify novel metabolic targets, including those involved in epigenetics, Fe-S biogenesis, and glycine biology, for diagnostic and therapeutic development.
BACKGROUND:Deficiencies of iron-sulfur (Fe-S) clusters, metal complexes that control redox state and mitochondrial metabolism, have been linked to pulmonary hypertension (PH), a deadly vascular disease with poorly defined molecular origins. BOLA3 (BolA Family Member 3) regulates Fe-S biogenesis, and mutations in BOLA3 result in multiple mitochondrial dysfunction syndrome, a fatal disorder associated with PH. The mechanistic role of BOLA3 in PH remains undefined. METHODS: In vitro assessment of BOLA3 regulation and gain- and loss-of-function assays were performed in human pulmonary artery endothelial cells using siRNA and lentiviral vectors expressing the mitochondrial isoform of BOLA3. Polymeric nanoparticle 7C1 was used for lung endothelium-specific delivery of BOLA3 siRNA oligonucleotides in mice. Overexpression of pulmonary vascular BOLA3 was performed by orotracheal transgene delivery of adeno-associated virus in mouse models of PH. RESULTS: In cultured hypoxic pulmonary artery endothelial cells, lung from humanpatients with Group 1 and 3 PH, and multiple rodent models of PH, endothelial BOLA3 expression was downregulated, which involved hypoxia inducible factor-2α-dependent transcriptional repression via histone deacetylase 1-mediated histone deacetylation. In vitro gain- and loss-of-function studies demonstrated that BOLA3 regulated Fe-S integrity, thus modulating lipoate-containing 2-oxoacid dehydrogenases with consequent control over glycolysis and mitochondrial respiration. In contexts of siRNA knockdown and naturally occurring human genetic mutation, cellular BOLA3 deficiency downregulated the glycine cleavage system protein H, thus bolstering intracellular glycine content. In the setting of these alterations of oxidative metabolism and glycine levels, BOLA3 deficiency increased endothelial proliferation, survival, and vasoconstriction while decreasing angiogenic potential. In vivo, pharmacological knockdown of endothelial BOLA3 and targeted overexpression of BOLA3 in mice demonstrated that BOLA3 deficiency promotes histological and hemodynamic manifestations of PH. Notably, the therapeutic effects of BOLA3 expression were reversed by exogenous glycine supplementation. CONCLUSIONS:BOLA3 acts as a crucial lynchpin connecting Fe-S-dependent oxidative respiration and glycine homeostasis with endothelial metabolic reprogramming critical to PH pathogenesis. These results provide a molecular explanation for the clinical associations linking PH with hyperglycinemic syndromes and mitochondrial disorders. These findings also identify novel metabolic targets, including those involved in epigenetics, Fe-S biogenesis, and glycine biology, for diagnostic and therapeutic development.
Authors: James E Dahlman; Carmen Barnes; Omar Khan; Aude Thiriot; Siddharth Jhunjunwala; Taylor E Shaw; Yiping Xing; Hendrik B Sager; Gaurav Sahay; Lauren Speciner; Andrew Bader; Roman L Bogorad; Hao Yin; Tim Racie; Yizhou Dong; Shan Jiang; Danielle Seedorf; Apeksha Dave; Kamaljeet S Sandu; Matthew J Webber; Tatiana Novobrantseva; Vera M Ruda; Abigail K R Lytton-Jean; Christopher G Levins; Brian Kalish; Dayna K Mudge; Mario Perez; Ludmila Abezgauz; Partha Dutta; Lynelle Smith; Klaus Charisse; Mark W Kieran; Kevin Fitzgerald; Matthias Nahrendorf; Dganit Danino; Rubin M Tuder; Ulrich H von Andrian; Akin Akinc; Avi Schroeder; Dipak Panigrahy; Victor Kotelianski; Robert Langer; Daniel G Anderson Journal: Nat Nanotechnol Date: 2014-05-11 Impact factor: 39.213
Authors: Evangelos D Michelakis; Vikram Gurtu; Linda Webster; Gareth Barnes; Geoffrey Watson; Luke Howard; John Cupitt; Ian Paterson; Richard B Thompson; Kelvin Chow; Declan P O'Regan; Lan Zhao; John Wharton; David G Kiely; Adam Kinnaird; Aristeidis E Boukouris; Chris White; Jayan Nagendran; Darren H Freed; Stephen J Wort; J Simon R Gibbs; Martin R Wilkins Journal: Sci Transl Med Date: 2017-10-25 Impact factor: 17.956
Authors: Stephen Y Chan; Ying-Yi Zhang; Craig Hemann; Christopher E Mahoney; Jay L Zweier; Joseph Loscalzo Journal: Cell Metab Date: 2009-10 Impact factor: 27.287
Authors: Dohoon Kim; Brian P Fiske; Kivanc Birsoy; Elizaveta Freinkman; Kenjiro Kami; Richard L Possemato; Yakov Chudnovsky; Michael E Pacold; Walter W Chen; Jason R Cantor; Laura M Shelton; Dan Y Gui; Manjae Kwon; Shakti H Ramkissoon; Keith L Ligon; Seong Woo Kang; Matija Snuderl; Matthew G Vander Heiden; David M Sabatini Journal: Nature Date: 2015-04-08 Impact factor: 49.962
Authors: Maki Niihori; Cody A Eccles; Sergey Kurdyukov; Marina Zemskova; Mathews Valuparampil Varghese; Anna A Stepanova; Alexander Galkin; Ruslan Rafikov; Olga Rafikova Journal: Am J Respir Cell Mol Biol Date: 2020-02 Impact factor: 6.914
Authors: Katherine Redinus; Jin Hyen Baek; Ayla Yalamanoglu; Hye Kyung H Shin; Radu Moldova; Julie W Harral; Delaney Swindle; David Pak; Scott K Ferguson; Rachelle Nuss; Kathryn Hassell; Eva Nozik-Grayck; Andre F Palmer; Mehdi A Fini; Vijaya Karoor; Kurt R Stenmark; Paul W Buehler; David C Irwin Journal: JCI Insight Date: 2019-08-08
Authors: Miranda K Culley; Jingsi Zhao; Yi Yin Tai; Ying Tang; Dror Perk; Vinny Negi; Qiujun Yu; Chen-Shan C Woodcock; Adam Handen; Gil Speyer; Seungchan Kim; Yen-Chun Lai; Taijyu Satoh; Annie Mm Watson; Yassmin Al Aaraj; John Sembrat; Mauricio Rojas; Dmitry Goncharov; Elena A Goncharova; Omar F Khan; Daniel G Anderson; James E Dahlman; Aditi U Gurkar; Robert Lafyatis; Ahmed U Fayyaz; Margaret M Redfield; Mark T Gladwin; Marlene Rabinovitch; Mingxia Gu; Thomas Bertero; Stephen Y Chan Journal: J Clin Invest Date: 2021-06-01 Impact factor: 14.808
Authors: Chen-Shan Chen Woodcock; Neha Hafeez; Adam Handen; Ying Tang; Lloyd D Harvey; Leonard E Estephan; Gil Speyer; Seungchan Kim; Thomas Bertero; Stephen Y Chan Journal: Am J Physiol Lung Cell Mol Physiol Date: 2021-02-10 Impact factor: 5.464